MET and neoplasm: The mechanisms of resistance in the remaining patients, as well as those treated with 3G EGFR TKIs, are thought to be diverse and include activation of alternative signaling pathways, such as MET or HER2 amplification, or phenotypic changes of the EMT process, which is also a key cellular phenomenon involved in tumor metastasis and progression (Erin et al., 2020; Vokes et al., 2022).